OpGen, Inc. (NASDAQ:OPGN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ME Staff 8-k
-
0

OpGen, Inc. (NASDAQ:OPGN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.

On June 8, 2017, the Annual Meeting of stockholders (the “Annual
Meeting”) of OpGen, Inc. (the “Company”) was held. The
information described in Item 5.07 of this Current Report on Form
8-K is incorporated herein by reference.
Laurence R. McCarthy, who was listed as a nominee for election as
a director in the Company’s Proxy Statement for the Annual
Meeting, withdrew his candidacy to be re-elected to the Board of
Directors on June 6, 2017, and, therefore, the Board of Directors
withdrew its nomination of him and established a slate of six
nominees for election to the Board at the meeting. After the
Annual Meeting, the newly elected Board of Directors. (the
“Board”) established the membership of the various Board
committees as follows:
Audit Committee
Compensation Committee
Compliance Committee
Harry J. D’Andrea (Chair)
Misti Ushio (Chair)
Tina S. Nova, Ph.D. (Chair)
David M. Rubin, Ph.D.
Timothy J.R. Harris, Ph.D. D.Sc.
Timothy J.R. Harris, Ph.D. D.Sc.
Misti Ushio, Ph.D.
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 8, 2017, the Company held its Annual Meeting for 2017. At
the Annual Meeting, the total number of shares represented in
person or by proxy was 22,870,324 of the 27,394,290 shares of
Common Stock outstanding and entitled to vote at the Annual
Meeting as of the record date, April 20, 2017. The following
matters were voted upon at the Annual Meeting:
1. Election of Directors. The following named persons were
elected as Directors of the Company to serve until the next
Annual Meeting of Stockholders in 2018 or until their successors
are elected and qualified. The votes cast were as follows:
Nominee
For
Vote Withheld
Evan Jones
13,650,428
190,865
Harry J. D’Andrea
13,692,913
148,380
Timothy J.R. Harris, Ph.D., D.Sc.
13,694,217
147,076
Tina S. Nova, Ph.D.
13,768,824
72,469
David M. Rubin, Ph.D.
13,692,264
149,029
Misti Ushio, Ph.D.
13,687,717
153,576
2. The vote of the stockholders to ratify the appointment of
CohnReznick LLP as the Company’s independent registered public
accounting firm for the fiscal year ending December 31, 2017,
was:
22,369,974 votes
FOR the resolution
245,369 votes
AGAINST the resolution
254,981 votes
ABSTAIN


About OpGen, Inc. (NASDAQ:OPGN)

OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company’s high-resolution DNA tests are marketed under the Acuitas trade name.